Browse > Article
http://dx.doi.org/10.5487/TR.2013.29.1.021

Biodistribution of 99mTc Labeled Integrin Antagonist  

Jang, Beom-Su (RI-Biomics Research & Development Team, Korea Atomic Energy Research Institute)
Park, Seung-Hee (Nuclear Medicine Department and Radiology Department, Warren G. Magnuson Clinical Center)
Shin, In Soo (Division of Biologics Research, Korea Food and Drug Administration)
Maeng, Jin-Soo (Bio-nanotechnology Research Center, Korea Food Research Institute)
Paik, Chang H. (Nuclear Medicine Department and Radiology Department, Warren G. Magnuson Clinical Center)
Publication Information
Toxicological Research / v.29, no.1, 2013 , pp. 21-25 More about this Journal
Abstract
The selective targeting of an integrin ${\alpha}_v{\beta}_3$ receptor using radioligands may enable the assessment of angiogenesis and integrin ${\alpha}_v{\beta}_3$ receptor status in tumors. The aim of this research was to label a peptidomimetic integrin ${\alpha}_v{\beta}_3$ antagonist (PIA) with $^{99m}Tc(CO)_3$ and to test its receptor targeting properties in nude mice bearing receptor-positive tumors. PIA was reacted with tris-succinimidyl aminotriacetate (TSAT) (20 mM) as a PIA per TSAT. The product, PIA-aminodiacetic acid (ADA), was radiolabeled with $[^{99m}Tc(CO)_3(H_2O)_3]^{+1}$, and purified sequentially on a Sep-Pak C-18 cartridge followed by a Sep-Pak QMA anion exchange cartridge. Using gradient C-18 reverse-phase HPLC, the radiochemical purity of $^{99m}Tc(CO)_3$-ADA-PIA (retention time, 10.5 min) was confirmed to be > 95%. Biodistribution analysis was performed in nude mice (n = 5 per time point) bearing receptor-positive M21 human melanoma xenografts. The mice were administered $^{99m}Tc(CO)_3$-ADA-PIA intravenously. The animals were euthanized at 0.33, 1, and 2 hr after injection for the biodistribution study. A separate group of mice were also co-injected with 200 ${\mu}g$ of PIA and euthanized at 1 hr to quantify tumor uptake. $^{99m}Tc(CO)_3$-ADA-PIA was stable in phosphate buffer for 21 hr, but at 3 and 6 hr, 7.9 and 11.5% of the radioactivity was lost as histidine, respectively. In tumor bearing mice, $^{99m}Tc(CO)_3$-ADA-PIA accumulated rapidly in a receptor-positive tumor with a peak uptake at 20 min, and rapid clearance from blood occurring primarily through the hepatobiliary system. At 20 min, the tumor-to-blood ratio was 1.8. At 1 hr, the tumor uptake was 0.47% injected dose (ID)/g, but decreased to 0.12% ID/g when co-injected with an excess amount of PIA, indicating that accumulation was receptor mediated. These results demonstrate successful $^{99m}TC$ labeling of a peptidomimetic integrin antagonist that accumulated in a tumor via receptor-specific binding. However, tumor uptake was very low because of low blood concentrations that likely resulted from rapid uptake of the agent into the hepatobiliary system. This study suggests that for $^{99m}Tc(CO)_3$-ADA-PIA to be useful as a tumor detection agent, it will be necessary to improve receptor binding affinity and increase the hydrophilicity of the product to minimize rapid hepatobiliary uptake.
Keywords
Peptidomimetic integrin ${\alpha}_v{\beta}_3$ antagonist; $^{99m}TC$ tricarbonyl precursor; Biodistribution;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Salignac, B., Grundler, P.V., Cayemittes, S., Frey, U., Scopelliti, R., Merbach, A.E., Hedinger, R., Hegetschweiler, K., Alberto, R., Prinz, U., Raabe, G., Kolle, U. and Hall, S. (2003) Reactivity of the organometallic $fac-[(CO)_{3}ReI(H_{2}O)_{3}]^{+}$ aquaion. Kinetic and thermodynamic properties of $H_{2}O$ substitution. Inorg. Chem., 42, 3516-3526.   DOI   ScienceOn
2 Trump, D.P., Mathias, C.J., Yang, Z., Low, P.S., Marmion, M. and Green, M.A. (2002) Synthesis and evaluation of $^{99m}Tc(CO)_{3}$- DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nucl. Med. Biol., 29, 569-573.   DOI   ScienceOn
3 Schibli, R. and Schubiger, P.A. (2002) Current use and future potential of organometallic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging, 29, 1529-1542.   DOI
4 Chen, X., Park, R., Shahinian, A.H., Bading, J.R. and Conti, P.S. (2004) Pharmacokinetics and tumor retention of 125Ilabeled RGD peptide are improved by PEGylation. Nucl. Med. Biol., 31, 11-19.   DOI   ScienceOn
5 Chen, X., Park, R., Hou, Y., Khankaldyyan, V., Gonzales- Gomez, I., Tohme, M., Bading, J.R., Laug, W.E. and Conti, P.S. (2004) MicroPET imaging of brain tumor angiogenesis with $^{18}F$-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging, 31, 1081-1089.
6 Chen, X., Hou, Y., Tohme, M., Park, R., Khankaldyyan, V., Gonzales-Gomez, I., Bading, J.R., Laug, W.E. and Conti, P.S. (2004) Pegylated Arg-Gly-Asp peptide: $^{64}Cu$ labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J. Nucl. Med., 45, 1776-1783.
7 Hood, J.D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R.A., Xiang, R. and Cheresh, D.A. (2002) Tumor regression by targeted gene delivery to the neovasculature. Sci., 296, 2404-2407.   DOI   ScienceOn
8 Burnett, C.A., Xie, J., Quijano, J., Shen, Z., Hunter, F., Bur, M., Li, K.C. and Danthi, S.N. (2005) Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor. Bioorg. Med. Chem., 13, 3763-3771.   DOI   ScienceOn
9 Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J.P., Plückthun, A. and Schubiger, P.A. (1999) Stable one-step technetium- 99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol., 17, 897-901.   DOI   ScienceOn
10 Schibli, R., Katti, K.V., Higginbotham, C., Volkert, W.A. and Alberto, R. (1999) In vitro and in vivo evaluation of bidentate, water-soluble phosphine ligands as anchor groups for the organometallic $fac-[^{99m}Tc(CO)_{3}]^{+}$-core. Nucl. Med. Biol., 26, 711-716.   DOI   ScienceOn
11 Schibli, R., La Bella, R., Alberto, R., Garcia-Garayoa, E., Ortner, K., Abram, U. and Schubiger, P.A. (2000) Influence of the denticity of ligand systems on the in vitro and in vivo behavior of $^{99m}Tc(I)$-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjugate Chem., 11, 345-351.   DOI   ScienceOn
12 Pietzsch, H.J., Gupta, A., Reisgys, M., Drews, A., Seifert, S., Syhre, R., Spies, H., Alberto, R., Abram, U., Schubiger, P.A. and Johannsen, B. (2000) Chemical and biological characterization of technetium(I) and Rhenium(I) tricarbonyl complexes with dithioether ligands serving as linkers for coupling the $Tc(CO)_{3}$ and $Re(CO)_{3}$ moieties to biologically active molecules. Bioconjugate Chem., 11, 414-424.   DOI   ScienceOn
13 Bullok, K.E., Dyszlewski, M., Prior, J.L., Pica, C.M., Sharma, V. and Piwnica-Worms, D. (2002) Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with (99m)Tc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy. Bioconjugate Chem., 13, 1226-1237.   DOI   ScienceOn
14 Pasqualini, R., Koivunen, E. and Ruoslahti, E. (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 15, 542-546.   DOI   ScienceOn
15 Haubner, R., Wester, H.J., Reuning, U., Senekowitsch- Schmidtke, R., Diefenbach, B., Kessler, H., Stocklin, G. and Schwaiger, M. (1999) Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med., 40, 1061-1071.
16 Chen, X., Park, R., Tohme, M., Shahinian, A.H., Bading, J.R. and Conti, P.S. (2004) MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using $^{18}F$- and $^{64}Cu$-labeled RGD peptide. Bioconjugate Chem., 15, 41-49.   DOI   ScienceOn
17 Smith, C.J., Sieckman, G.L., Owen, N.K., Hayes, D.L., Mazuru, D.G., Kannan, R., Volkert, W.A. and Hoffman, T.J. (2003) Radiochemical investigations of gastrin-releasing peptide receptor-specific [$^{99m}Tc(X)(CO)_{3}$-Dpr-Ser-Ser-Ser-Gln- Trp-Ala-Val-Gly-His-Leu-Met-($NH_{2}$)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = $H_{2}O$ or $P(CH_{2}OH)_{3}$. Cancer Res., 63, 4082-4088.
18 van Hagen, P.M., Breeman, W.A., Bernard, H.F., Schaar, M., Mooij, C.M., Srinivasan, A., Schmidt, M.A., Krenning, E.P. and de Jong, M. (2000) Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer, 90, 186-198.   DOI
19 Haubner, R., Bruchertseifer, F., Bock, M., Kessler, H., Schwaiger, M. and Wester, H.J. (2004) Synthesis and biological evaluation of a $^{99m}Tc$-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin, 43, 26-32.
20 Harris, T.D., Kalogeropoulos, S., Nguyen, T., Liu, S., Bartis, J., Ellars, C., Edwards, S., Onthank, D., Silva, P., Yalamanchili, P., Robinson, S., Lazewatsky, J., Barrett, J. and Bozarth, J. (2003) Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm., 18, 627-641.   DOI   ScienceOn
21 Onthank, D.C., Liu, S., Silva, P.J., Barrett, J.A., Harris, T.D., Robinson, S.P. and Edwards, D.S. (2004) $^{90}Y$ and $^{111}In$ complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent. Bioconjugate Chem., 15, 235-241.   DOI   ScienceOn
22 Li, L., Wartchow, C.A., Danthi, S.N., Shen, Z., Dechene, N., Pease, J., Choi, H.S., Doede, T., Chu, P., Ning, S., Lee, D.Y., Bednarski, M.D. and Knox, S.J. (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated $^{90}Y$-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys., 58, 1215-1227.   DOI   ScienceOn
23 Haubner, R., Wester, H.J., Burkhart, F., Senekowitsch- Schmidtke, R., Weber, W., Goodman, S.L., Kessler, H. and Schwaiger, M. (2001) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med., 42, 326-336.